Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PRO.MED.CS Praha

PRO.MED.CS Praha a.s. is a Czech pharmaceutical Company located in Prague specialising in the manufacture of solid medicinal forms – tablets, film coated tablets and capsules. Our medicinal portfolio is primarily aimed at the cardiovascular, gastrointestinal and musculoskeletal areas and pain. We also provide medicines for mental disorders, bacterial and viral diseases. In addition to prescription medicines we produce over the counter medicines and trace elements too.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

PRO.MED.CS Praha
Telcska 1, Prague, 140 00, Czech Republic
+420 241 013 111
Contact PRO.MED.CS Praha
Website

 Latest Content from PMHub 

Improving healthcare for rare disease patients

White Papers and Resources | March 4, 2022 | IGNIFI

Following on from Rare Disease Day 2022, we decided to take a deeper look into the patient journey of those living with a rare health condition. In this blog, we...

Gamifying Remote Patient Monitoring

Videos and Podcasts | March 3, 2022 | Impetus Digital

Dr. Emilia Molimpakis, CEO & Co-founder of Thymia, shares how their platform uses video games based on neuropsychology, alongside analyses of facial microexpressions and speech, to quickly, accurately, and objectively...

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Press Releases | March 3, 2022 | Avalere Health

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...

Onyx Health Announces a “Double Hatrick” of New Appointments

Press Releases | March 3, 2022 | Onyx Health

Onyx Health continues to expand with six new appointments to its creative and communication teams, due to increased growth in its international client portfolio work.

Utilising Patient Insight in Pharma Marketing

White Papers and Resources | March 3, 2022 | Dice Medical Communications

The importance in understanding the patients view point when marketing in Pharma (Article written August 30th 2021)

Office move signals new era for Berkshire agency

Press Releases | March 3, 2022 | Dice Medical Communications

Dice Medical Communications moves office due to business growth

How Ease of Access to HES Data Benefits HCPs & Key NHS Stakeholders

White Papers and Resources | March 3, 2022 | Dice Medical Communications

Article written August 27th 2021

How a Copywriter Reads a Clinical Paper

White Papers and Resources | March 2, 2022 | Dice Medical Communications

What key elements you need to consider in a clinical paper (Article written November 18th 2021)

What does HCP engagement look like in a post-Covid world?

White Papers and Resources | March 2, 2022 | Dice Medical Communications

HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...

Placing people at Lucid’s heart: Paul Cutler, Lucid Group’s new Chief People Officer

Press Releases | March 2, 2022 | Lucid Group Communications Limited

We interviewed Paul Cutler, Lucid Group’s new Chief People Officer, to find out a bit more about what makes him tick, why he chose to join Lucid, and what his...